Back to News
Market Impact: 0.2
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
Source: zacks.com
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Wall Street analysts’ average price target implies 39.7% potential upside for Viridian Therapeutics (VRDN), though the article cautions that price targets are a questionable metric. Positive earnings estimate revisions may support the stock, but no target price, revision figures, or market reaction are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
VRDN0.30
More News
- Axon Enterprise earnings analysis: questions answered and next catalysts
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Doximity earnings analysis: questions answered and next catalysts
- Jefferies raises Mettler-Toledo stock price target on solid growth
- Bremmer: U.S. Retreat From Global Leadership Is a Long-Term Shift